2009-12-13 00:40:56 -
Fast Market Research recommends "Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth" from Datamonitor, now available
The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches see the Parkinson's disease market grow at a compound annual growth rate (CAGR) of 2.6% over the next 10 years (20082018).
Scope
* In-depth analysis of the current and future Parkinson's disease market across the US, Japan, France, Germany, Italy, Spain and the UK.
* Parkinson's disease-specific sales forecasts for brands and generics from 2008 to 2018.
* Assessment of the leading Parkinson's disease brands and drug classes to identify key success factors within this market.
* Evaluation of the strategies of leading players in the
Parkinson's disease market.
Highlights
Stalevo's clear convenience and compliance benefit will see the combination therapy emerge as the market leading brand between 2011 and 2013.
Although Boehringer Ingelheim is relatively late to the market with a once-daily reformulation, Mirapex/Sifrol's (pramipexole) dominant share of some geographic markets will facilitate a successful launch in 2010.
Over the 10-year forecast period the US market will lose significance for Parkinson's disease market players as demographic changes and a less competitive commercial environment will see the European and Japanese markets emerge as key generators of growth.
Partial Table of Contents:
-- Full ToC is available at
www.fastmr.com/catalog/product.aspx?productid=43005&dt=t
ABOUT DATAMONITOR HEALTHCARE
About the CNS pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor insight into the Parkinson's disease market
Related reports
Upcoming reports
CHAPTER 2 MARKET DEFINITION
Market definition for this report
CHAPTER 3 MARKET OVERVIEW
Seven major markets
Current and future market overview
Opportunities and threats
Opportunity - Aging population
Opportunity - Better symptomatic treatment
Opportunity - Development of neuroprotectants
Opportunity - Patch formulations
Threat - Maturing drug classes
Threat - Global economic downturn
US
Current and future market assessment
Opportunities and threats
Opportunity - Quicker accurate diagnosis
Opportunity - High public awareness drives access to funding
Opportunity - Extra NIH funding
Opportunity - Stem cell therapy research
Threat - Generic incursion of the dopamine agonist class
Threat - Growing number of unemployed patients in the US
Japan
Current and future market assessment
Opportunities and threats
Opportunity - Large and growing elderly population
Opportunity - Entry into an underdeveloped market
Threat - Greater generic incursion expected over the forecast period
Five major European markets (5EU)
Current and future market assessment
Opportunities and threats
Opportunity - Price premium for diseases with high unmet need
Opportunity - 'Get it on time' campaign
Threat - Immature generics markets to grow
Threat - EU Commission reviews online drug information
Threat - Regulatory changes may facilitate entry of generics
France
Current and future market assessment
Germany
Current and future market assessment
Italy
Current and future market assessment
Spain
Current and future market assessment
UK
Current and future market assessment
Rest of the world snapshot
Current market assessment
CHAPTER 4 BRAND DYNAMICS
Overview of competitive landscape
Patient acquisition process
Introduction
Patient care path
Points of influence in the patient care path
Early incorporation of Azilect (rasagaline, Lundbeck/Teva) into the treatment algorithm?
Dopamine agonist or levodopa therapy?
Add Comtan or switch to Stalevo?
Apomorphine or Duodopa (Carbidopa, Solvay)?
Drivers of brand choice
Ability to control motor symptoms
Cost
Side-effect profile
Patient convenience
Potential neuroprotective properties
US formulary tier status for leading brands
Mirapex and pramipexole ER (pramipexole, Boehringer Ingelheim)
Drug overview
Drug profile
Product positioning
Movement from supportive to monotherapy role
Development of pramipexole extended-release
SWOT analysis
Brand forecast to 2018
Generic set to enter the market earlier than patent expiry
Requip and Requip XL (ropinirole extended-release; GlaxoSmithKline)
Drug overview
Drug profile
Product positioning
Movement from supportive to monotherapy role
Superiority of XL version to IR version suggested
SWOT analysis
Brand forecast to 2018
Switching from Mirapex to Requip XL
10-year forecast
Neupro (rotigotine CDS, UCB)
Drug overview
Drug profile
Product positioning
SWOT analysis
Brand forecast to 2018
Azilect (rasagiline, Teva/Lundbeck)
Drug overview
Drug profile
Mechanism of action
Product positioning
For more information or to purchase this report, go to
www.fastmr.com/catalog/product.aspx?productid=43005
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at
www.fastmr.com/catalog/publishers.aspx?pubid=1002
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at
www.fastmr.com or call us at 1.800.844.8156.
